The toxicity of β-amyloid is attenuated by interaction with its specific human scFv E3 in vitro

Life Sciences

Volumn 82, Issue 25-26, 2008, Pages 1249-1255

  Yue, Shen ^a   Li, Yue ^a   Wang, Xiaohua ^a   Bai, Hui ^a   Xia, Jun ^a   Jiang, Li ^a   Ji, Yong ^a   Fan, Leming ^a   He, Zhigang ^a   Chen, Qi ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

amyloid; Aggregation; Alzheimer's disease; In vitro; Neurotoxicity; Single chain variable domain antibody fragment

Indexed keywords

AMYLOID BETA PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

AGED; ANTIGEN BINDING; ARTICLE; BRAIN CORTEX; FIBER; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR RECOGNITION; NEUROTOXICITY; PROTEIN AGGREGATION; PROTEIN INTERACTION;

AGED; AMYLOID BETA-PROTEIN; ANTIBODIES; BACTERIOPHAGES; BLOTTING, WESTERN; CELL DEATH; CELL LINE, TUMOR; CEREBRAL CORTEX; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOHISTOCHEMISTRY; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY;

EID: 44649166288     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.04.009     Document Type: Article

References (52)

1. Akiyama H., Barger S., Barnum S., Brad B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., and Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiology of Aging 21 (2000) 383-421
2. Alvarez A.R., Godoy J.A., Mullendorff K., Olivares G.H., Bronfman M., and Inestrosa N.C. Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Experimental Cell Research 297 (2004) 186-196
3. Bacskai B.J., Kajdasz S.T., McLellan M.E., Games D., Seubert P., Schenk D., and Hyman B.T. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. The Journal of Neuroscience 22 (2002) 7873-7878
4. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., and Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Medicine 6 (2000) 916-919
5. Chauhan N.B., and Siegel G.J. Intracerebroventricular passive immunization with anti-A beta antibody in Tg2576. Journal of Neuroscience Research 74 (2003) 142-147
6. Chirita C., Necula M., and Kuret J. Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 43 (2004) 2879-2887
7. Citron M. Strategies for disease modification in Alzheimer's disease. Nature Reviews Neuroscience 5 (2004) 677-685
8. Cummings J.L. Alzheimer's disease. New England Journal of Medicine 351 (2004) 56-67
9. Cutler R.G., Kelly J., Storie K., Pedersen W.A., Tammara A., Hatanpaa K., Troncoso J.C., and Mattson M.P. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proceedings of the National Academy of Sciences USA 101 (2004) 2070-2075
10. D'Andrea M.R., Nagele R.G., Wang H.Y., Peterson P.A., and Lee D.H.S. Evidence that neurons accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology 38 (2001) 120-134
11. D'Andrea M.R., Nagele R.G., Wang H.Y., and Lee D.H.S. Consistent immunohistochemical detection of intracellular β-amyloid42 in pyramidal neurons of Alzheimer's disease entorhinal cortex. Neuroscience Letters 333 (2002) 163-166
12. Dahlgren K.N., Manelli A.M., Stine Jr. W.B., Baker L.K., Krafft G.A., and LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. The Journal of Biological Chemistry 277 (2002) 32046-32053
13. Danielsson J., Jarvet J., Damberg P., and Graslund A. The Alzheimer beta-peptide shows temperature-dependent transitions between left-handed 3-helix, beta-strand and random coil secondary structures. FEBS Journal 272 (2005) 3938-3949
14. de Bruin R., Spelt K., Mol J., Koes R., and Quattrocchio F. Selection of high-affinity phage antibodies from phage display libraries. Nature Biotechnology 17 (1999) 397-399
15. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences USA 98 (2001) 8850-8855
16. Deshpande A., Mina E., Glabe C., and Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. The Journal of Neuroscience 26 (2006) 6011-6018
17. Dong L., Chen S., and Schachner M. Single chain Fv antibodies against neural cell adhesion molecule L1 trigger L1 functions in cultured neurons. Molecular and Cellular Neuroscience 22 (2003) 234-247
18. Erica C. Nerve inflammation halts trial for Alzheimer's drug. Nature 415 (2002) 462
19. Fezoui Y., Hartley D.M., Harper J.D., Khurana R., Walsh D.M., Condron M.M., Selkoe D.J., Lansbury Jr. P.T., Fink A.L., and Teplow D.B. An improved method of preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments. Amyloid 7 (2000) 166-178
20. Fukuchi K., Tahara K., Kim H.D., Maxwell J.A., Lewis T.L., Accavitti-Loper M.A., Kim H., Ponnazhagan S., and Lalonde R. Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiology of Disease 23 3 (2006) 502-511
21. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., and Klein W.L. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proceedings of the National Academy of Sciences USA 100 (2003) 10417-10422
22. Green P.S., Perez E.J., Calloway T., and Simpkins J.W. Estradiol attenuation of beta-amyloid-induced toxicity: a comparison of MTT and calcein AM assays. Journal of Neurocytology 29 5-6 (2000) 419-423
23. Ha C., Ryu J., and Park C.B. Metal ions differentially influence the aggregation and deposition of Alzheimer's beta-amyloid on a solid template. Biochemistry 46 (2007) 6118-6125
24. Habicht G., Haupt C., Friedrich R.P., Hortschansky P., Sachse C., Meinhardt J., Wieligmann K., Gellermann G.P., Brodhun M., Götz J., Halbhuber K.J., Röcken C., Horn U., and Fändrich M. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils. Proceedings of the National Academy of Sciences USA 104 (2007) 19232-19237
25. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
26. Kheterpal I., Chen M., Cook K.D., and Wetzel R. Structural differences in Abeta amyloid protofibrils and fibrils mapped by hydrogen exchange-mass spectrometry with on-line proteolytic fragmentation. Journal of Molecular Biology 361 (2006) 785-795
27. Lee E.B., Leng L.Z., Zhang B., Kwong L., Trojanowski J.Q., Abel T., and Lee V.M. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. The Journal of Biological Chemistry 281 (2006) 4292-4299
28. Lesné S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., and Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 (2006) 284-285
29. LeVine H. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Science 2 (1993) 404-410
30. Liu R., Yuan B., Emadi S., Zameer A., Schulz P., McAllister C., Lyubchenko Y., Goud G., and Sierks M.R. Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry 43 (2004) 6959-6967
31. Look G.C., Jerecic J., Cherbavaz D.B., Pray T.R., Breach J.C., Crosier W.J., Igoudin L., Hironaka C.M., Lowe R.M., McEntee M., Ruslim-Litrus L., Wu H.M., Zhang S., Catalano S.M., Goure W.F., Summa D., and Krafft G.A. Discovery of ADDL-targeting small molecule drugs for Alzheimer's disease. Current Alzheimer Research 4 (2007) 562-567
32. Lorenzo A., and Yankner B.A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proceedings of the National Academy of Sciences USA 91 (1994) 12243-12247
33. Mamikonyan G., Necula M., Mkrtichyan M., Ghochikyan A., Petrushina I., Movsesyan N., Mina E., Kiyatkin A., Glabe C.G., Cribbs D.H., and Agadjanyan M.G. Anti-Abeta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. The Journal of Biological Chemistry 282 (2007) 76-86
34. Melnikova I. Therapies for Alzheimer's disease. Nature Review. Drug Discovery 6 (2007) 341-342
35. Miles L.A., Wun K.S., Crespi G.A., Fodero-Tavoletti M.T., Galatis D., Bagley C.J., Beyreuther K., Masters C.L., Cappai R., McKinstry W.J., Barnham K.J., and Parker M.W. Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope. Journal of Molecular Biology 377 (2008) 181-192
36. Morgan D., and Gitter B.D. Evidence supporting a role for anti-Abeta antibodies in the treatment of Alzheimer's disease. Neurobiology of Aging 25 (2004) 605-608
37. Pini A., and Bracci L. Phage display of antibody fragments. Current Protein and Peptide Science 1 (2000) 155-169
38. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., and Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
39. Solomon B. Anti-aggregating antibodies, a new approach towards treatment of conformational diseases. Current Medicinal Chemistry 9 (2002) 1737-1749
40. Solomon B., Koppel R., Frankel D., and Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proceedings of the National Academy of Sciences USA 94 (1997) 109-4112
41. Solórzano-Vargas R.S., Vasilevko V., Acero G., Ugen K.E., Martinez R., Govezensky T., Vazquez-Ramirez R., Kubli-Garfias C., Cribbs D.H., Manoutcharian K., and Gevorkian G. Epitope mapping and neuroprotective properties of a human single chain FV antibody that binds an internal epitope of amyloid-beta 1-42. Molecular Immunology 45 (2008) 881-886
42. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nature Reviews Neuroscience 4 (2003) 49-60
43. Soto C., Branes M.C., Alvarez J., and Inestrosa N.C. Structural determinants of the Alzheimer's amyloid beta-peptide. Journal of Neurochemistry 63 (1994) 1191-1198
44. Syme C.D., Nadal R.C., Rigby S.E., and Viles J.H. Copper binding to the amyloid-beta (Abeta) peptide associated with Alzheimer's disease: folding, coordination geometry, pH dependence, stoichiometry, and affinity of Abeta-(1-28): insights from a range of complementary spectroscopic techniques. Journal of Biological Chemistry 279 (2004) 18169-18177
45. Tampellini D., Magrane J., Takahashi R.H., Li F., Lin M.T., Almeida C.G., and Gouras G.K. Internalized antibodies to the Aβ domain of APP reduce neuronal Aβ and protect against synaptic alterations. Journal of Biological Chemistry 282 (2007) 18895-18906
46. Taylor B.M., Sarver R.W., Fici G., Poorman R.A., Lutzke B.S., Molinari A., Kawabe T., Kappenman K., Buhl A.E., and Epps D.E. Spontaneous aggregation and cytotoxicity of the beta-amyloid Abeta1-40: a kinetic model. Journal of Protein Chemistry 22 (2003) 31-40
47. Wang Y.J., Pollard A., Zhong J.H., Dong X.Y., Wu X.B., Zhou H.D., and Zhou X.F. Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease. Neurobiology of Aging (2007) 2007 August 7th (Electronic publication)
48. Wilcock D.M., DiCarlo G., Henderson D., Jackson J., Clarke K., Ugen K.E., Gordon M.N., and Morgan D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. The Journal of Neuroscience 23 (2003) 3745-3751
49. Wirths O., Multhaup G., Czech C., Blanchard V., Moussaoui S., Tremp G., Pradier L., Beyreuther K., and Bayer T.A. Intraneuronal Aβ accumulation precedes plaque formation in β-amyloid precursor protein and presenilin-1 double-transgenic mice. Neuroscience Letters 306 (2001) 116-120
50. Yan S.D., Zhu H., Zhu A., Golabek A., Du H., Roher A., Yu J., Soto C., Schmidt A.M., Stern D., and Kindy M. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nature Medicine 6 (2000) 643-651
51. Zameer A., Schulz P., Wang M.S., and Sierks M.R. Single chain Fv antibodies against the 25-35 Abeta fragment inhibit aggregation and toxicity of Abeta42. Biochemistry 45 38 (2006) 11532-11539
52. Zhu X., Smith M.A., Perry G., and Aliev G. Mitochondrial failures in Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias 19 (2004) 345-352